Overview

Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease

Status:
Completed

Trial end date:
2021-03-04

Target enrollment:

Participant gender:

Summary

For therapy of symptomatic premature ventricular complexes (PVCs) in subjects with structural heart disease the current European Guidelines for the management of patients with ventricular arrhythmias and the prevention of second cardiac death recommend catheter ablation as well as amiodarone with a class IIa indication. Due to the lack of randomized data this study investigates the comparison of catheter ablation and amiodarone for PVC treatment in patients with structural heart disease. Therefore, patients will be randomized to one of two treatment strategies: 1) catheter ablation, or 2) amiodarone.

Phase:

Phase 3

Details

Lead Sponsor:

Heartcenter Leipzig GmbH
University of Leipzig

Collaborators:

Abbott Medical Devices
Leipzig Heart Institute GmbH
Zentrum für Klinische Studien Leipzig

Treatments:

Amiodarone
Anti-Arrhythmia Agents
Flecainide
Propafenone